{'fraction_non_alphanumeric': 0.013870541611624834, 'fraction_numerical': 0.0033025099075297227, 'mean_word_length': 5.158536585365853, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 2, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Methodological shortcomings in the reports of the imiquimod psoriatic model

Psoriasis is a chronic inflammatory skin disease affecting about 2–3% of the worldwide population. More of the knowledge of psoriasis is due to the in vitro and in vivo models tried to reproduce the disease and to know the mechanisms of pathogenesis, as well as to develop new therapies. One of the more simple, cheap and more used models is the imiquimod model based on the application of imiquimod in the depilated skin of mice. Several studies describing the methodology employed to develop an animal disease model does not present all the details about the model more especially related to the use of one sex or another and other methodological aspects that are relevant for researchers and to consider the accuracy of the study. In this review, we have selected 100 papers published in the last five years using the imiquimod psoriatic model recording different data such as animal, strain, sex, dose of imiquimod, area of administration, housing information, anaesthesia/euthanasia information, number of animals per group and control details among others. Our results revealed several methodological shortcomings in the models of imiquimod to study psoriasis namely sex bias and discrepancies in dose applied or time of imiquimod application among others. As long as these discrepancies exist in animal methodologies, there will be a poor translation from animal studies to clinical applications in dermatology and in other areas.